0.59 USD
↗ 0.02 (3.13%)AT CLOSE (03:59 PM EDT)
Outlook Therapeutics, Inc. Common Stock
OTLKNASDAQ • USD
0.60
↗ 0.00 (0.51%)
POST MARKET (AS OF 07:59 PM EDT)
Post Market
AS OF 07:59 PM EDT
0.60
↗ 0.00 (0.51%)
Market: CLOSED
Outlook Therapeutics, Inc. Common Stock (OTLK) is currently trading at $0.59. Both sides of the analysis point lower: technicals flash "Sell" and fundamentals confirm with a "Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, exceptional Return on Equity (460.2%) and a bullish Golden Cross on the moving averages.
Technical & fundamental data as of Oct 2, 2026.
Open?$0.59
High?$0.61
Low?$0.57
Prev. Close?$0.58
Volume?5.6M
Avg. Volume?5.9M
VWAP?$0.58
Rel. Volume?0.96x
Bid / Ask
Bid?$0.51 × 100
Ask?$0.68 × 100
Spread?$0.17
Midpoint?$0.59
Valuation & Ratios
Market Cap?143.6M
Shares Out?243.4M
Float?83.0M
Float %?99.9%
P/E Ratio?N/A
P/B Ratio?-13.82
EPS?-$0.20
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Employees
17
Market Cap
144.4M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2016-05-13
Address
111 S. WOOD AVENUE
ISELIN, NJ 08830
Phone: (609) 619-3990
ISELIN, NJ 08830
Phone: (609) 619-3990
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?12
Z-Score?0
Momentum?29
Short Sent.?36
Piotroski F-Score?2/9Weak
Altman Z-Score?-37.71Distress
Confidence?63%Moderate
Short InterestSqueeze Risk
Short % of Float?38.82%Squeeze Risk
Short Interest?32.2M
Days to Cover?7.7
Free Float83.0M
Avg Daily Volume4.2M
Settlement Date2026-09-15
Financial Health
Current Ratio?0.81Weak
Quick Ratio?0.63Weak
Cash Ratio?0.39Low
Debt/Equity?-1.75Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?-13.82CHEAP▾
S&P97
P/S?-134.03CHEAP▾
S&P97
P/FCF?N/A▾
EV/EBITDA?-3.9CHEAP▾
S&P97
EV/Sales?-140.54CHEAP▾
S&P97
Returns & Efficiency
ROE?460.2%STRONG▾
Peers50
S&P97
ROA?-182.7%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-56154885
Enterprise Value?$150.6M
Fundamentals ratios updated end of day